Literature DB >> 17623052

Long-term consequences of domino liver transplantation using familial amyloidotic polyneuropathy grafts.

Shinji Yamamoto1, Henryk E Wilczek, Takashi Iwata, Marie Larsson, Henrik Gjertsen, Gunnar Söderdahl, Göran Solders, Bo-Göran Ericzon.   

Abstract

Domino liver transplantation (DLT) using grafts from patients with familial amyloidotic polyneuropathy (FAP) is an established procedure at many transplantation centers. However, data evaluating the long-term outcome of DLT are limited. The aim of the present study was to analyze the risk of de novo polyneuropathy, possibly because of amyloidosis, and the patient survival after DLT. At our department, 28 DLT using FAP grafts were conducted between January 1997 and December 2005. One patient was twice subjected to DLT. Postoperative neurological monitoring of peripheral nerve function was performed with electroneurography (ENeG) in 20 cases. An ENeG index based on 12 parameters was calculated and correlated to age and/or height. Three patients developed ENeG signs of polyneuropathy 2-5 years after the DLT, but with no clinical symptoms. The 1-, 3- and 5-year actuarial patient survival in hepatocellular carcinoma (HCC) patients (n = 12) and non-HCC patients (n = 15) was 67%, 15%, 15% and 93%, 93%, 80%, respectively (P = 0.001). Development of impaired nerve conduction in a proportion of patients may indicate that de novo amyloidosis occurs earlier than previously expected. Survival after DLT was excellent except in patients with advanced HCC.

Entities:  

Mesh:

Year:  2007        PMID: 17623052     DOI: 10.1111/j.1432-2277.2007.00516.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  4 in total

1.  Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?

Authors:  Joel N Buxbaum; Clement Tagoe; Gloria Gallo; John R Walker; Sunil Kurian; Daniel R Salomon
Journal:  FASEB J       Date:  2012-02-23       Impact factor: 5.191

2.  Treatment With Diflunisal in Domino Liver Transplant Recipients With Acquired Amyloid Neuropathy.

Authors:  Velina Nedkova-Hristova; Carmen Baliellas; José González-Costello; Laura Lladó; Emma González-Vilatarsana; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Transpl Int       Date:  2022-04-13       Impact factor: 3.842

3.  Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.

Authors:  Richard M Giadone; Derek C Liberti; Taylor M Matte; Jessica D Rosarda; Celia Torres-Arancivia; Sabrina Ghosh; Jolene K Diedrich; Sandra Pankow; Nicholas Skvir; J C Jean; John R Yates; Andrew A Wilson; Lawreen H Connors; Darrell N Kotton; R Luke Wiseman; George J Murphy
Journal:  Stem Cell Reports       Date:  2020-07-30       Impact factor: 7.765

4.  Domino-liver transplantation: toward a safer and simpler technique in both donor and recipient.

Authors:  Jan Lerut; Maxime Foguenne; Quirino Lai; Jean de Ville de Goyet
Journal:  Updates Surg       Date:  2020-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.